DanCann Pharma AS (XSAT:DANCAN) Construction In Progress: kr0.10 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DANCAN DanCann Pharma AS XSAT:DANCAN
24 GF Score
Price kr0.14
GF Value kr0.52
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS Construction In Progress?

DanCann Pharma AS XSAT:DANCAN -2.78% 24 Construction In Progress is kr0.10 Mil as of Sep. 2025. GuruFocus rates XSAT:DANCAN with a GF Score™ of 24/100 and a GF Value™ of kr0.52. The stock has 3 warning signs investors should review.

DanCann Pharma AS's quarterly construction in progress stayed the same from Mar. 2025 (kr0.10 Mil) to Jun. 2025 (kr0.10 Mil) and stayed the same from Jun. 2025 (kr0.10 Mil) to Sep. 2025 (kr0.10 Mil).

DanCann Pharma AS's annual construction in progress declined from Dec. 2022 (kr3.35 Mil) to Dec. 2023 (kr0.10 Mil) but then stayed the same from Dec. 2023 (kr0.10 Mil) to Dec. 2024 (kr0.10 Mil).

DanCann Pharma AS Construction In Progress Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS Construction In Progress Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
Get a 7-Day Free Trial 1.95 3.32 3.35 0.10 0.10

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.10 0.10 0.10
XSAT:DANCAN
24GF Score
DanCann Pharma AS XSAT:DANCAN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of kr0.10 Mil mean?
DanCann Pharma AS (XSAT:DANCAN) has a Construction In Progress of kr0.10 Mil as of Sep. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Construction In Progress too high?
DanCann Pharma AS's current Construction In Progress is kr0.10 Mil. Overall, DanCann Pharma AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Construction In Progress compare to ZTS and UTHR?
DanCann Pharma AS's Construction In Progress of kr0.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on DanCann Pharma AS and its competitors. DanCann Pharma AS's current Construction In Progress is kr0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (XSAT:DANCAN) has a current Construction In Progress of kr0.10 Mil. The stock's GF Value™ is kr0.52, compared to a current price of kr0.14 — trading 73.1% below its estimated fair value. The current Construction In Progress is kr0.10 Mil. DanCann Pharma AS's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For DanCann Pharma AS (XSAT:DANCAN), the current Construction In Progress is kr0.10 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (XSAT:DANCAN) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of kr0.14 is trading 73.1% below its estimated GF Value™ of kr0.52.

Key valuation signals for XSAT:DANCAN:

  • Construction In Progress: kr0.10 Mil
  • GF Value™: kr0.52 vs. price of kr0.14 (73.1% below fair value)
  • GF Score™: 24/100 with 3 warning signs

No single metric tells the full story. See the XSAT:DANCAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
24GF Score

Get the complete analysis for XSAT:DANCAN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.14
Price
kr0.52
GF Value